Summary
The provided AI claims are about drug-test detection windows (urine/blood/saliva/hair) and testing interpretations, but the supplied FDA label excerpts do not contain any information supporting or refuting these claims. As a result, the response is largely unsupported by the provided prescribing information.
Category Scores
Accurate Statements
Suboxone contains buprenorphine and naloxone.
Consistent with the provided label excerpts describing SUBOXONE as buprenorphine/naloxone (e.g., Sections 1 and 5.2/5.1 excerpts).
If Suboxone is taken as prescribed, disclosing it and providing documentation such as a prescription and medication list can be appropriate.
Not directly stated in the provided excerpts; however, Section 17 includes patient counseling content about overdose reversal agents rather than drug-testing disclosure. Therefore, label support is absent for this specific claim.
Many testing programs include confirmatory testing that can distinguish buprenorphine from other opioids.
No confirmatory testing details are present in the supplied label excerpts.
Unsupported Statements
The length of time Suboxone/buprenorphine stays detectable depends on the drug test type, metabolism, dose, and duration of use.
No drug-detection or toxicology testing guidance is present in the supplied label excerpts.
With typical urine drug testing, buprenorphine can be detectable for several days after the last dose.
No urine detection window information appears in the supplied label excerpts.
With typical urine drug testing, many people see buprenorphine detection results within about a week.
No urine detection window information appears in the supplied label excerpts.
Detection windows for buprenorphine on urine testing can be longer with heavier or longer-term use.
No detection window information appears in the supplied label excerpts.
Blood and saliva tests usually detect drugs for a shorter time than urine.
No detection window or specimen-type comparison information appears in the supplied label excerpts.
Hair tests can detect drug traces for much longer than urine.
No hair testing or detection window information appears in the supplied label excerpts.
In urine drug testing, buprenorphine is generally detectable for multiple days.
No urine detection window information appears in the supplied label excerpts.
A rule of thumb used by clinicians is that buprenorphine may be detectable on urine testing for roughly up to 3–7 days.
No detection window or clinician rule-of-thumb information appears in the supplied label excerpts.
Buprenorphine detection on urine testing can be longer depending on dose and frequency.
No detection window information appears in the supplied label excerpts.
Test sensitivity and specific cutoff levels affect whether buprenorphine is detected on urine testing.
No discussion of test sensitivity/cutoffs is present in the supplied label excerpts.
If a test is looking specifically for buprenorphine rather than a standard panel, detection results can differ.
No drug panel/detection specificity guidance is present in the supplied label excerpts.
Longer-term use and higher doses can increase the likelihood of detectable levels lingering longer, especially in urine testing.
No detection window/dose-duration relationship is present in the supplied label excerpts.
Body fat and liver metabolism can affect how long buprenorphine remains detectable.
No pharmacokinetic/detection-duration modifiers are present in the supplied label excerpts.
Suboxone can continue to have effects even after the drug concentration declines.
No statement about ongoing effects independent of concentration is present in the supplied label excerpts.
Blood and saliva detection windows are usually shorter than urine.
No detection window/specimen comparison information appears in the supplied label excerpts.
In general terms, detection of buprenorphine on blood or saliva tests is commonly on the order of roughly a day for many people.
No blood/saliva detection window information appears in the supplied label excerpts.
Exact timing of buprenorphine detection in blood or saliva varies by dose and testing method.
No detection window/timing information appears in the supplied label excerpts.
Hair testing can detect drug use over a much longer period because it reflects drug incorporation as hair grows.
No hair testing mechanism or detection-duration explanation appears in the supplied label excerpts.
Hair test detection for Suboxone can last weeks to months.
No hair detection window information appears in the supplied label excerpts.
Hair test detection for Suboxone can last sometimes longer depending on hair length tested and individual hair growth rates.
No hair detection window or hair-length/growth-rate modifiers appear in the supplied label excerpts.
Some standard drug panels may miss buprenorphine unless the lab specifically tests for it.
No panel/detection specificity guidance appears in the supplied label excerpts.
Confirmatory tests such as GC/MS or LC/MS can find smaller amounts than screening tests.
No laboratory testing method details (GC/MS, LC/MS) appear in the supplied label excerpts.
Results can shift based on when the last dose was taken.
No drug-testing timing guidance appears in the supplied label excerpts.
If Suboxone is taken as prescribed, disclosing it and providing documentation such as a prescription and medication list can be appropriate.
No drug-testing disclosure/documentation guidance appears in the supplied label excerpts.
Contradictions
Important Omissions
The AI response does not cite or reflect any on-label SUBOXONE counseling content relevant to safety (e.g., overdose reversal agent access, respiratory/CNS depression warnings, and dental care instructions).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
The response’s primary claims concern drug-test detection windows and lab testing behavior, which are not addressed in the provided label excerpts. Because the label content to validate safety-critical testing assertions is absent, the alignment cannot be confirmed; however, the response also does not directly provide dosing or contraindicated-use instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are about specimen drug-detection windows and testing procedures, which are not supported by the supplied FDA labeling excerpts.
Suggested Improvement
Restrict claims to information explicitly present in the provided label excerpts (e.g., indication, dosing/administration instructions, contraindications, and on-label safety counseling such as overdose reversal agent guidance), or provide label excerpts that specifically address drug testing/detection windows.